Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11

GlobeNewswire June 23, 2021

Medicenna Reports Fiscal Year 2021 Financial Results and Operational Highlights

GlobeNewswire May 28, 2021

Medicenna to Announce Fiscal Year 2021 Financial Results and Operational Highlights on Friday, May 28, 2021

GlobeNewswire May 20, 2021

Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer

GlobeNewswire May 12, 2021

Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma

GlobeNewswire May 7, 2021

Medicenna Therapeutics (TSX:MDNA) appoints Dr. Kevin Moulder as Chief Scientific Officer

Julia Kennedy  April 21, 2021

Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer

GlobeNewswire April 21, 2021

Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 14, 2021

Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting

GlobeNewswire April 12, 2021

Medicenna (TSX:MDNA) unveils bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit

Brieanna McCutcheon  March 25, 2021

Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit

GlobeNewswire March 25, 2021

Medicenna Therapeutics Announces Upcoming Presentation at the AACR Annual Meeting 2021

GlobeNewswire March 11, 2021

Medicenna Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire March 4, 2021

Medicenna to Present at the Cowen 41st Annual Healthcare Conference

GlobeNewswire February 22, 2021

Medicenna to Present at the 10th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 17, 2021

Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights

GlobeNewswire February 12, 2021

Medicenna Establishes At-the-Market Sales Facility

GlobeNewswire December 30, 2020

Medicenna Announces Oral Presentation at the 2nd Annual Glioblastoma Drug Development Summit

GlobeNewswire December 9, 2020

Medicenna Hosting Key Opinion Leader Call on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme

GlobeNewswire December 2, 2020

Medicenna to Participate in Upcoming December Investor Conferences

GlobeNewswire November 23, 2020